...
首页> 外文期刊>Oncogene >Functional expression of the CXCR4 chemokine receptor is induced by RET|[sol]|PTC oncogenes and is a common event in human papillary thyroid carcinomas
【24h】

Functional expression of the CXCR4 chemokine receptor is induced by RET|[sol]|PTC oncogenes and is a common event in human papillary thyroid carcinomas

机译:RET | [sol] | PTC癌基因可诱导CXCR4趋化因子受体的功能性表达,在人乳头状甲状腺癌中是常见事件

获取原文
           

摘要

To identify genes involved in the transformation of thyroid follicular cells, we explored, using DNA oligonucleotide microarrays, the transcriptional response of PC Cl3 rat thyroid epithelial cells to the ectopic expression of the RET/PTC oncogenes. We found that RET/PTC was able to induce the expression of CXCR4, the receptor for the chemokine CXCL12/SDF-1/. We observed that CXCR4 expression correlated with the transforming ability of the oncoprotein and depended on the integrity of the RET/PTC–RAS/ERK signaling pathway. We found that CXCR4 was expressed in RET/PTC-positive human thyroid cancer cell lines, but not in normal thyroid cells. Furthermore, we found CXCR4 expression in human thyroid carcinomas, but not in normal thyroid samples by immunohistochemistry. Since CXCR4 has been recently implicated in tumor proliferation, motility and invasiveness, we asked whether treatment with SDF-1 was able to induce a biological response in thyroid cells. We observed that SDF-1 induced S-phase entry and survival of thyroid cells. Invasion through a reconstituted extracellular matrix was also supported by SDF-1 and inhibited by a blocking antibody to CXCR4. Taken together, these results suggest that human thyroid cancers bearing RET/PTC rearrangements may use the CXCR4/SDF-1 receptor–ligand pathway to proliferate, survive and migrate.
机译:为了鉴定参与甲状腺滤泡细胞转化的基因,我们使用DNA寡核苷酸微阵列探索了PC Cl3大鼠甲状腺上皮细胞对RET / PTC癌基因异位表达的转录反应。我们发现RET / PTC能够诱导趋化因子CXCL12 / SDF-1 /的受体CXCR4的表达。我们观察到CXCR4的表达与癌蛋白的转化能力相关,并取决于RET / PTC-RAS / ERK信号通路的完整性。我们发现CXCR4在RET / PTC阳性人甲状腺癌细胞系中表达,但在正常甲状腺细胞中不表达。此外,通过免疫组织化学,我们发现CXCR4在人甲状腺癌中表达,但在正常甲状腺样品中未发现。由于CXCR4最近与肿瘤增殖,运动性和侵袭性有关,我们询问用SDF-1进行的治疗是否能够在甲状腺细胞中诱导生物学反应。我们观察到,SDF-1诱导甲状腺细胞S期进入和存活。 SDF-1也支持通过重构的细胞外基质的侵袭,并受到针对CXCR4的封闭抗体的抑制。综上所述,这些结果表明,携带RET / PTC重排的人类甲状腺癌可能使用CXCR4 / SDF-1受体-配体途径来增殖,存活和迁移。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号